Mode
Text Size
Log in / Sign up

Post-hoc analysis of RCTs and cohorts identifies predictors of remission in ACPA-positive early RA treated with abatacept plus methotrexate or methotrexate alone.

Post-hoc analysis of RCTs and cohorts identifies predictors of remission in ACPA-positive early RA t…
Photo by Sasun Bughdaryan / Unsplash
Key Takeaway
Consider that only baseline disease activity and early DAS response consistently predict remission in ACPA-positive early RA.

This post-hoc analysis combined data from the AVERT and AVERT-II randomized controlled trials with an observational cohort from the Leiden Early Arthritis Clinic. The study population consisted of ACPA-positive patients with early rheumatoid arthritis, comprising 388 individuals in the methotrexate monotherapy group and 743 in the abatacept plus methotrexate group. The primary outcome assessed was DAS28-CRP remission at 6 and 12 months of follow-up.

At 6 months, DAS28 remission was achieved by 27% of patients in the methotrexate monotherapy group compared to 43% in the abatacept plus methotrexate group. By 12 months, remission rates increased to 39% for the methotrexate group and 53% for the combination therapy group. Additionally, model performance for predicting remission at 6 and 12 months was evaluated using AUROC scores of 0.66 and 0.65 for the methotrexate group, and 0.68 and 0.59 for the abatacept plus methotrexate group, respectively.

Safety data, including adverse events, serious adverse events, discontinuations, and tolerability, were not reported in the provided evidence. A key limitation of this analysis is that adding baseline MRI-detected joint inflammation, baseline serology, or HLA-shared epitope alleles did not significantly improve the predictive model performance. Consequently, the study indicates that determining which patients will achieve clinical remission remains challenging.

The practice relevance highlights that while disease activity at presentation and early DAS response are consistent predictors, other biomarkers offer limited additional value. Clinicians should interpret these findings with restraint, recognizing that the evidence is derived from post-hoc analyses of specific trial populations and observational cohorts where causality cannot be definitively established.

Study Details

Study typeRct
Sample sizen = 388
EvidenceLevel 2
Follow-up12.0 mo
PublishedApr 2026
View Original Abstract ↓
OBJECTIVE: To predict which early RA-patients achieve clinical remission on initial treatment with methotrexate monotherapy or with abatacept+methotrexate. METHODS: This study is a subanalysis of the AVERT and AVERT-2 randomized controlled trials, which were performed in ACPA-positive early RA-patients who received methotrexate monotherapy or abatacept + methotrexate. External model validation of patients on methotrexate monotherapy was performed in the observational Leiden Early Arthritis Clinic (EAC) cohort. Primary outcome was DAS28-CRP remission at 6 and 12 months follow-up. Prediction models were developed using logistic regression analysis. First, a model including clinical baseline variables only was estimated. Subsequently, it was assessed whether adding serological or imaging data, shared epitope or early DAS28 response improved model performance. RESULTS: In the methotrexate-monotherapy group (n=388), 27% and 39% of patients achieved DAS28-remission after 6 and 12-months. In the abatacept + methotrexate group (n=743) this was 43% and 53%. Baseline DAS28-CRP was predictive for clinical remission in all models. Optimism-adjusted model performance (AUROC) for DAS28-remission at 6 and 12-months was 0.66/0.65 in the methotrexate-group and 0.68/0.59 in the abatacept + methotrexate group. Adding baseline MRI-detected joint-inflammation, baseline serology or HLA-shared epitope alleles did not significantly improve model performance. Early DAS28-response did improve model performance. In the external validation cohort model performance was very similar. CONCLUSION: Determining which patients achieve clinical remission upon methotrexate or abatacept+methotrexate treatment remains challenging. Disease activity at disease presentation and early DAS response were the only consistent predictors for achieving clinical remission. Genetic, imaging and serology parameters did not improve model performance.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.